SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Erol B) "

Sökning: WFRF:(Erol B)

  • Resultat 1-45 av 45
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • 2021
  • swepub:Mat__t
  •  
3.
  • 2021
  • swepub:Mat__t
  •  
4.
  • Bravo, L, et al. (författare)
  • 2021
  • swepub:Mat__t
  •  
5.
  • Tabiri, S, et al. (författare)
  • 2021
  • swepub:Mat__t
  •  
6.
  • Glasbey, JC, et al. (författare)
  • 2021
  • swepub:Mat__t
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • Gross, Sean M., et al. (författare)
  • A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses
  • 2022
  • Ingår i: Communications Biology. - : Springer Nature. - 2399-3642. ; 5:1
  • Tidskriftsartikel (refereegranskat)abstract
    • The phenotype of a cell and its underlying molecular state is strongly influenced by extracellular signals, including growth factors, hormones, and extracellular matrix proteins. While these signals are normally tightly controlled, their dysregulation leads to phenotypic and molecular states associated with diverse diseases. To develop a detailed understanding of the linkage between molecular and phenotypic changes, we generated a comprehensive dataset that catalogs the transcriptional, proteomic, epigenomic and phenotypic responses of MCF10A mammary epithelial cells after exposure to the ligands EGF, HGF, OSM, IFNG, TGFB and BMP2. Systematic assessment of the molecular and cellular phenotypes induced by these ligands comprise the LINCS Microenvironment (ME) perturbation dataset, which has been curated and made publicly available for community-wide analysis and development of novel computational methods ( synapse.org/LINCS_MCF10A ). In illustrative analyses, we demonstrate how this dataset can be used to discover functionally related molecular features linked to specific cellular phenotypes. Beyond these analyses, this dataset will serve as a resource for the broader scientific community to mine for biological insights, to compare signals carried across distinct molecular modalities, and to develop new computational methods for integrative data analysis.
  •  
11.
  • Girt, Erol, et al. (författare)
  • A method for measuring exchange stiffness in ferromagnetic films
  • 2011
  • Ingår i: Journal of Applied Physics. - : AIP Publishing. - 0021-8979 .- 1089-7550. ; 109:7, s. 07B765-
  • Tidskriftsartikel (refereegranskat)abstract
    • An exchange stiffness, A(ex), in ferromagnetic films is obtained by fitting the M(H) dependence of two ferromagnetic layers antiferromagnetically coupled across a nonmagnetic spacer layer with a simple micromagnetic model. In epitaxial and textured structures this method allows measuring A(ex) between the crystallographic planes perpendicular to the growth direction of ferromagnetic films. Our results show that A(ex) between [0001] planes in textured Co grains is 1.54 +/- 0.12 x 10(-11) J/m.
  •  
12.
  • Ivanova, M.Y, et al. (författare)
  • Testing Syndromes of Psychopathology in Parent and Youth Ratings Across Societies
  • 2019
  • Ingår i: Journal of clinical child and adolescent psychology. - : Informa UK Limited. - 1537-4416 .- 1537-4424. ; 48:4, s. 596-609
  • Tidskriftsartikel (refereegranskat)abstract
    • As societies become increasingly diverse, mental health professionals need instruments for assessing emotional, behavioral, and social problems in terms of constructs that are supported within and across societies. Building on decades of research findings, multisample alignment confirmatory factor analyses tested an empirically based 8-syndrome model on parent ratings across 30 societies and youth self-ratings across 19 societies. The Child Behavior Checklist for Ages 6–18 and Youth Self-Report for Ages 11–18 were used to measure syndromes descriptively designated as Anxious/ Depressed, Withdrawn/Depressed, Somatic Complaints, Social Problems, Thought Problems, Attention Problems, Rule-Breaking Behavior, and Aggressive Behavior. For both parent ratings (N = 61,703) and self-ratings (N = 29,486), results supported aggregation of problem items into 8 first-order syndromes for all societies (configural invariance), plus the invariance of item loadings (metric invariance) across the majority of societies. Supported across many societies in both parent and self-ratings, the 8 syndromes offer a parsimonious phenotypic taxonomy with clearly operatio- nalized assessment criteria. Mental health professionals in many societies can use the 8 syndromes to assess children and youths for clinical, training, and scientific purposes.
  •  
13.
  •  
14.
  • Halvorsen, Sigrun, et al. (författare)
  • Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation : observations from the ARISTOTLE trial
  • 2014
  • Ingår i: European Heart Journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 35:28, s. 1864-1872
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death, and bleeding. We evaluated these outcomes in relation to patient age. Methods and results A total of 18 201 patients with AF and a raised risk of stroke were randomized to warfarin or apixaban 5 mg b.d. with dose reduction to 2.5 mg b.d. or placebo in 831 patients with >= 2 of the following criteria: age >= 80 years, body weight <= 60 kg, or creatinine >= 133 mu mol/L. We used Cox models to compare outcomes in relation to patient age during 1.8 years median follow-up. Of the trial population, 30% were <65 years, 39% were 65 to <75, and 31% were >= 75 years. The rates of stroke, all-cause death, and major bleeding were higher in the older age groups (P < 0.001 for all). Apixaban was more effective than warfarin in preventing stroke and reducing mortality across all age groups, and associated with less major bleeding, less total bleeding, and less intracranial haemorrhage regardless of age (P interaction >0.11 for all). Results were also consistent for the 13% of patients >= 80 years. No significant interaction with apixaban dose was found with respect to treatment effect on major outcomes. Conclusion The benefits of apixaban vs. warfarin were consistent in patients with AF regardless of age. Owing to the higher risk at older age, the absolute benefits of apixaban were greater in the elderly.
  •  
15.
  • Hill, JA, et al. (författare)
  • Medical Misinformation
  • 2019
  • Ingår i: Circulation. Cardiovascular interventions. - 1941-7632. ; 12:2, s. e007796-
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
16.
  • Hill, JA, et al. (författare)
  • Medical Misinformation
  • 2019
  • Ingår i: Hypertension (Dallas, Tex. : 1979). - 1524-4563. ; 73:3, s. 506-507
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
17.
  • Hill, JA, et al. (författare)
  • Medical Misinformation
  • 2019
  • Ingår i: Circulation. Heart failure. - 1941-3297. ; 12:2, s. e005869-
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
18.
  • Hill, JA, et al. (författare)
  • Medical Misinformation
  • 2019
  • Ingår i: Circulation. Cardiovascular imaging. - 1942-0080. ; 12:2, s. e008809-
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
19.
  • Hill, JA, et al. (författare)
  • Medical Misinformation
  • 2019
  • Ingår i: Circulation. Genomic and precision medicine. - 2574-8300. ; 12:2, s. e002439-
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
20.
  • Hill, JA, et al. (författare)
  • Medical Misinformation
  • 2019
  • Ingår i: Circulation. - 1524-4539. ; 139:5, s. 571-572
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
21.
  • Hill, JA, et al. (författare)
  • Medical Misinformation
  • 2019
  • Ingår i: Circulation. Cardiovascular quality and outcomes. - 1941-7705. ; 12:2, s. e005496-
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
22.
  • Hill, JA, et al. (författare)
  • Medical misinformation: vet the message!
  • 2019
  • Ingår i: Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. - : Springer Science and Business Media LLC. - 1572-8595. ; 55:1, s. 1-3
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
23.
  • Hill, JA, et al. (författare)
  • Medical misinformation: Vet the message!
  • 2019
  • Ingår i: Journal of electrocardiology. - : Elsevier BV. - 1532-8430 .- 0022-0736. ; 53, s. 112-113
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
24.
  • Hill, JA, et al. (författare)
  • Medical misinformation: vet the message!
  • 2019
  • Ingår i: Cardiovascular research. - : Oxford University Press (OUP). - 1755-3245 .- 0008-6363.
  • Tidskriftsartikel (refereegranskat)
  •  
25.
  • Hill, JA, et al. (författare)
  • Medical Misinformation: Vet the Message!
  • 2019
  • Ingår i: Cardiovascular drugs and therapy. - : Springer Science and Business Media LLC. - 1573-7241 .- 0920-3206. ; 33:3, s. 275-276
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
26.
  • Hill, JA, et al. (författare)
  • Medical Misinformation: Vet the Message!
  • 2019
  • Ingår i: International journal of cardiology. - : Elsevier BV. - 1874-1754 .- 0167-5273. ; 277, s. 1-2
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
27.
  • Hill, JA, et al. (författare)
  • Medical Misinformation: Vet the Message!
  • 2019
  • Ingår i: Journal of the American Heart Association. - 2047-9980. ; 8:3, s. e011838-
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
28.
  •  
29.
  • Hill, JA, et al. (författare)
  • Medical misinformation: vet the message!
  • 2019
  • Ingår i: European heart journal. Quality of care & clinical outcomes. - : Oxford University Press (OUP). - 2058-1742 .- 2058-5225. ; 5:2, s. 83-84
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
30.
  • Hill, JA, et al. (författare)
  • Medical misinformation: vet the message!
  • 2019
  • Ingår i: European heart journal. Cardiovascular pharmacotherapy. - : Oxford University Press (OUP). - 2055-6845 .- 2055-6837. ; 5:2, s. 62-63
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
31.
  • Hill, JA, et al. (författare)
  • Medical misinformation: Vet the message!
  • 2019
  • Ingår i: Heart rhythm. - : Elsevier BV. - 1556-3871 .- 1547-5271. ; 16:3, s. 332-333
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
32.
  • Hill, JA, et al. (författare)
  • Medical Misinformation: Vet the Message!
  • 2019
  • Ingår i: Journal of cardiovascular pharmacology. - 1533-4023. ; 73:2, s. 61-62
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
33.
  • Hill, JA, et al. (författare)
  • Medical misinformation: vet the message!
  • 2019
  • Ingår i: European journal of heart failure. - : Wiley. - 1879-0844 .- 1388-9842. ; 21:3, s. 264-265
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
34.
  • Hill, JA, et al. (författare)
  • Medical misinformation: vet the message!
  • 2019
  • Ingår i: Cardiovascular research. - : Oxford University Press (OUP). - 1755-3245 .- 0008-6363. ; 115:14, s. E187-E188
  • Tidskriftsartikel (refereegranskat)
  •  
35.
  • Ivanova, M. Y., et al. (författare)
  • Effects of individual differences, society, and culture on youth-rated problems and strengths in 38 societies
  • 2022
  • Ingår i: Journal of Child Psychology and Psychiatry. - : Wiley. - 0021-9630 .- 1469-7610. ; 63:11, s. 1297-1307
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Clinicians increasingly serve youths from societal/cultural backgrounds different from their own. This raises questions about how to interpret what such youths report. Rescorla et al. (2019, European Child & Adolescent Psychiatry, 28, 1107) found that much more variance in 72,493 parents' ratings of their offspring's mental health problems was accounted for by individual differences than by societal or cultural differences. Although parents' reports are essential for clinical assessment of their offspring, they reflect parents' perceptions of the offspring. Consequently, clinical assessment also requires self-reports from the offspring themselves. To test effects of individual differences, society, and culture on youths' self-ratings of their problems and strengths, we analyzed Youth Self-Report (YSR) scores for 39,849 11-17 year olds in 38 societies. Methods: Indigenous researchers obtained YSR self-ratings from population samples of youths in 38 societies representing 10 culture cluster identified in the Global Leadership and Organizational Behavioral Effectiveness study. Hierarchical linear modeling of scores on 17 problem scales and one strengths scale estimated the percent of variance accounted for by individual differences (including measurement error), society, and culture cluster. ANOVAs tested age and gender effects. Results: Averaged across the 17 problem scales, individual differences accounted for 92.5% of variance, societal differences 6.0%, and cultural differences 1.5%. For strengths, individual differences accounted for 83.4% of variance, societal differences 10.1%, and cultural differences 6.5%. Age and gender had very small effects. Conclusions: Like parents' ratings, youths' self-ratings of problems were affected much more by individual differences than societal/cultural differences. Most variance in self-rated strengths also reflected individual differences, but societal/cultural effects were larger than for problems, suggesting greater influence of social desirability. The clinical significance of individual differences in youths' self-reports should thus not be minimized by societal/cultural differences, which-while important-can be taken into account with appropriate norms, as can gender and age differences.
  •  
36.
  • Lopes, Renato D., et al. (författare)
  • Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation : a secondary analysis of a randomised controlled trial
  • 2012
  • Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 380:9855, s. 1749-1758
  • Tidskriftsartikel (refereegranskat)abstract
    • Background The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in lower mortality. We assessed in this trial's participants how results differed according to patients' CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, used to predict the risk of stroke and bleeding. Methods ARISTOTLE was a double-blind, randomised trial that enrolled 18 201 patients with atrial fibrillation in 39 countries. Patients were randomly assigned apixaban 5 mg twice daily (n=9120) or warfarin (target international normalised ratio 2.0-3.0; n=9081). The primary endpoint was stroke or systemic embolism. The primary safety outcome was major bleeding. We calculated CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores of patients at randomisation. Efficacy analyses were by intention to treat, and safety analyses were of the population who received the study drug. ARISTOTLE is registered with ClinicalTrials.gov, number NCT00412984. Findings Apixaban significantly reduced stroke or systemic embolism with no evidence of a differential effect by risk of stroke (CHADS(2) 1, 2, or >= 3, p for interaction=0.4457; or CHA(2)DS(2)VASc 1, 2, or >= 3, p for interaction=0.1210) or bleeding (HAS-BLED 0-1, 2, or >= 3, p for interaction=0.9422). Patients who received apixaban had lower rates of major bleeding than did those who received warfarin, with no difference across all score categories (CHADS(2), p for interaction=0.4018; CHA(2)DS(2)VASc, p for interaction=0.2059; HAS-BLED, p for interaction=0.7127). The relative risk reduction in intracranial bleeding tended to be greater in patients with HAS-BLED scores of 3 or higher (hazard ratio [HR] 0.22, 95% CI 0.10-0.48) than in those with HAS-BLED scores of 0-1 (HR 0.66, 0.39-1.12; p for interaction=0.0604). Interpretation Because apixaban has benefits over warfarin that are consistent across patient risk of stroke and bleeding as assessed by the CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, these scores might be less relevant when used to tailor apixaban treatment to individual patients than they are for warfarin. Further improvement in risk stratification for both stroke and bleeding is needed, particularly for patients with atrial fibrillation at low risk for these events.
  •  
37.
  •  
38.
  • Ozantürk, Ayşegül, et al. (författare)
  • The phenotypic and molecular genetic spectrum of Alström syndrome in 44 Turkish kindreds and a literature review of Alström syndrome in Turkey
  • 2015
  • Ingår i: International Journal of Human Genetics. - New York, USA : Nature Publishing Group. - 0972-3757 .- 1434-5161 .- 1435-232X. ; 60:1, s. 1-9
  • Tidskriftsartikel (refereegranskat)abstract
    • Alstrom syndrome (ALMS) is an autosomal recessive disease characterized by multiple organ involvement, including neurosensory vision and hearing loss, childhood obesity, diabetes mellitus, cardiomyopathy, hypogonadism, and pulmonary, hepatic, renal failure and systemic fibrosis. Alstrom Syndrome is caused by mutations in ALMS1, and ALMS1 protein is thought to have a role in microtubule organization, intraflagellar transport, endosome recycling and cell cycle regulation. Here, we report extensive phenotypic and genetic analysis of a large cohort of Turkish patients with ALMS. We evaluated 61 Turkish patients, including 11 previously reported, for both clinical spectrum and mutations in ALMS1. To reveal the molecular diagnosis of the patients, different approaches were used in combination, a cohort of patients were screened by the gene array to detect the common mutations in ALMS1 gene, then in patients having any of the common ALMS1 mutations were subjected to direct DNA sequencing or next-generation sequencing for the screening of mutations in all coding regions of the gene. In total, 20 distinct disease-causing nucleotide changes in ALMS1 have been identified, eight of which are novel, thereby increasing the reported ALMS1 mutations by 6% (8/120). Five disease-causing variants were identified in more than one kindred, but most of the alleles were unique to each single patient and identified only once (16/20). So far, 16 mutations identified were specific to the Turkish population, and four have also been reported in other ethnicities. In addition, 49 variants of uncertain pathogenicity were noted, and four of these were very rare and probably or likely deleterious according to in silico mutation prediction analyses. ALMS has a relatively high incidence in Turkey and the present study shows that the ALMS1 mutations are largely heterogeneous; thus, these data from a particular population may provide a unique source for the identification of additional mutations underlying Alstrom Syndrome and contribute to genotype-phenotype correlation studies.
  •  
39.
  • Pol, Tymon, et al. (författare)
  • Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy : Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial
  • 2018
  • Ingår i: Journal of the American Heart Association. - : WILEY. - 2047-9980. ; 7:3
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundDyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients with atrial fibrillation receiving oral anticoagulation. Methods and ResultsUsing data from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, ApoA1 and ApoB plasma levels were measured at baseline in 14884 atrial fibrillation patients. Median length of follow-up was 1.9years. Relationships between continuous levels of ApoA1 and ApoB and clinical outcomes were evaluated using Cox models adjusted for cardiovascular risk factors, medication including statins, and cardiovascular biomarkers. A composite ischemic outcome (ischemic stroke, systemic embolism, myocardial infarction, and cardiovascular death) was used as the primary end point. Median (25th, 75th) ApoA1 and ApoB levels were 1.10 (0.93, 1.30) and 0.70g/L (0.55, 0.85), respectively. In adjusted analyses, higher levels of ApoA1 were independently associated with a lower risk of the composite ischemic outcome (hazard ratio, 0.81; P<0.0001). Similar results were observed for the individual components of the composite outcome. ApoB was not significantly associated with the composite ischemic outcome (P=0.8240). Neither apolipoprotein was significantly associated with major bleeding. There was no interaction between lipoproteins and randomized treatment for the primary outcome (both P values 0.2448). ConclusionsIn patients with atrial fibrillation on oral anticoagulation, higher levels of ApoA1 were independently associated with lower risk of ischemic cardiovascular outcomes. Investigating therapies targeting dyslipidemia may thus be useful to improve cardiovascular outcomes in patients with atrial fibrillation. Clinical Trial RegistrationURL: . Unique identifier: NCT00412984.
  •  
40.
  •  
41.
  • Rao, Meena P, et al. (författare)
  • Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation : Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
  • 2015
  • Ingår i: Journal of the American Heart Association. - 2047-9980. ; 4:12
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Patients with atrial fibrillation (AF) and hypertension are at high risk for stroke. Previous studies have shown elevated risk of stroke in patients with AF who have a history of hypertension (regardless of blood pressure [BP] control) and in patients with elevated BP. We assessed the association of hypertension and BP control on clinical outcomes.METHODS AND RESULTS: In ARISTOTLE (n=18 201), BP was evaluated as history of hypertension requiring treatment and elevated BP (systolic ≥140 and/or diastolic ≥90 mm Hg) at study entry and any point during the trial. Hazard ratios (HRs) were derived from Cox proportional hazards models including BP as a time-dependent covariate. A total of 15 916 (87.5%) patients had a history of hypertension requiring treatment. In patients with elevated BP measurement at any point during the trial, the rate of stroke or systemic embolism was significantly higher (HR, 1.53; 95% confidence interval [CI], 1.25-1.86), as was hemorrhagic stroke (HR 1.85; 95% CI, 1.26-2.72) and ischemic stroke (HR, 1.50; 95% CI, 1.18-1.90). Rates of major bleeding were lower in patients with a history of hypertension (HR, 0.80; 95% CI, 0.66-0.98) and nonsignificantly lower in patients with elevated BP at study entry (HR, 0.89; 95% CI, 0.77-1.03). The benefit of apixaban versus warfarin on preventing stroke or systemic embolism was consistent among patients with and without a history of hypertension (P interaction=0.27), BP control at baseline (P interaction=0.43), and BP control during the trial (P interaction=0.97).CONCLUSIONS: High BP measurement at any point during the trial was independently associated with a substantially higher risk of stroke or systemic embolism. These results strongly support efforts to treat elevated BP as an important strategy to optimally lower risk of stroke in patients with AF.CLINICAL TRIAL REGISTRATION: URL: https://ClinicalTrials.gov/. Unique identifier: NCT00412984.
  •  
42.
  •  
43.
  • Wallentin, Lars, et al. (författare)
  • Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation
  • 2013
  • Ingår i: Circulation. - 0009-7322 .- 1524-4539. ; 127:22, s. 2166-2176
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundIn the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation to 2 predictions of time in therapeutic range (TTR).Methods and ResultsThe trial randomized 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or warfarin for at least 12 months. For each patient, a center average TTR was estimated with the use of a linear mixed model on the basis of the real TTRs in its warfarin-treated patients, with a fixed effect for country and random effect for center. For each patient, an individual TTR was also predicted with the use of a linear mixed effects model including patient characteristics as well. Median center average TTR was 66% (interquartile limits, 61% and 71%). Rates of stroke or systemic embolism, major bleeding, and mortality were consistently lower with apixaban than with warfarin across center average TTR and individual TTR quartiles. In the lowest and highest center average TTR quartiles, hazard ratios for stroke or systemic embolism were 0.73 (95% confidence interval [CI], 0.53–1.00) and 0.88 (95% CI, 0.57–1.35) (Pinteraction=0.078), for mortality were 0.91 (95% CI, 0.74–1.13) and 0.91 (95% CI, 0.71–1.16) (Pinteraction=0.34), and for major bleeding were 0.50 (95% CI, 0.36–0.70) and 0.75 (95% CI, 0.58–0.97) (Pinteraction=0.095), respectively. Similar results were seen for quartiles of individual TTR.ConclusionsThe benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers’ and patients’ predicted quality of international normalized ratio control.Clinical Trial RegistrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.
  •  
44.
  •  
45.
  • Zahedi, Sadaf, et al. (författare)
  • Information Quality Aware Sensor Network Services
  • 2008
  • Ingår i: Proc. 42nd Asilomar Conference on Signals, Systems and Computers. - Piscataway, NJ : IEEE. - 9781424429400 ; , s. 1155-1159
  • Konferensbidrag (refereegranskat)
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-45 av 45

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy